Full Press Release Details
Pharma to Present Five Preclinical Studies from Innovative Pipeline at American Association of Cancer Research (AACR) Annual Meeting
MD, and SUZHOU, China, March 25, 2025-Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company engaged
in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for hematological malignancies,
today announced that five abstracts highlighting the latest preclinical results from its pipeline programs have been selected for presentations
at the 2025 American Association of Cancer Research Annual Meeting (AACR), taking place April 25-30, 2025, in Chicago, Illinois, USA.
data to be presented encompasses five of the company's novel drug candidates: BCR-ABL tyrosine kinase inhibitor olverembatinib
(HQP1351), Bcl-2 inhibitor lisaftoclax (APG-2575), FAK/ALK/ROS1 tyrosine kinase inhibitor APG-2449, EED inhibitor APG-5918, and IAP antagonist
AACR Annual Meeting is the critical driver of progress against cancer, the place where scientists, clinicians, other health care professionals,
survivors, patients, and advocates gather to share and discuss the latest breakthroughs. From population science and prevention; to cancer
biology, translational, and clinical studies; to survivorship and advocacy; the AACR Annual Meeting showcases cutting-edge cancer science
five preclinical abstracts from Ascentage Pharma include:
(HQP1351) in combination with lisaftoclax (APG-2575) overcomes venetoclax resistance in preclinical models of acute myeloid leukemia
of olverembatinib (HQP1351) in combination with BCL-2 inhibitor lisaftoclax (APG-2575) in T-cell acute lymphoblastic leukemia (T-ALL)
ectoderm development protein (EED) inhibitor APG-5918 exhibits potent antitumor activity and synergizes with androgen receptor (AR) inhibitor
enzalutamide in preclinical prostate cancer (PCa) models
a novel focal adhesion kinase (FAK) inhibitor, enhances the antitumor activity of chemotherapy in preclinical models of small-cell lung
cancer (SCLC) with activated FAK
of AS03157 as a highly potent and orally active antagonist of inhibitor of apoptosis proteins (IAPs)
is an investigational drug and is not approved in the U.S.
Pharma is a global, integrated biopharmaceutical company engaged in discovering, developing and commercializing therapies to address
global unmet medical needs primarily in hematological malignancies. Ascentage Pharma has been listed on the Main Board of the Stock Exchange
of Hong Kong Limited with the stock code 6855.HK since October 2019 and has also been listed on the Nasdaq Global Market under the ticker
symbol "AAPG" since January 2025.
company has built a rich pipeline of innovative drug candidates that includes inhibitors targeting key proteins in the apoptotic pathway,
such as Bcl-2 and MDM2-p53; and next-generation TKIs that target kinase mutants emergent during cancer treatment. Ascentage Pharma is
also the only company in the world with active clinical programs targeting all known key apoptosis regulators. The company has conducted
more than 40 clinical trials in the US, Australia, Europe, and China, including 11 completed or ongoing US/global registrational trials
on the company's 5 key clinical-stage assets, of which 2 trials are regulated by the US FDA.
one of the company's lead assets, is already approved in China with all of its approved indications included into the China National
Reimbursement Drug List (NRDL). Meanwhile, a New Drug Application (NDA) for another one of Ascentage Pharma's key drug candidates,
the novel Bcl-2 selective inhibitor lisaftoclax (APG-2575), has already been accepted and granted the Priority Review designation by
date, Ascentage Pharma has obtained a total of 16 ODDs from the US FDA and 1 Orphan Designation from the EMA of the EU for 4 of the company's
investigational drug candidates. Leveraging its robust R&D capabilities, Ascentage Pharma has built a portfolio of global intellectual
property rights and entered into global partnerships and other relationships with numerous leading biotechnology and pharmaceutical companies
such as Takeda, AstraZeneca, Merck, Pfizer and Innovent; and research and development relationships with leading research institutions
such as Dana-Farber Cancer Institute, Mayo Clinic, National Cancer Institute and the University of Michigan.
company has built a talented team with a wealth of global experience in the discovery and development of innovative drugs and fully functional
commercial manufacturing and Sales & Marketing teams. One pivotal aim of Ascentage Pharma is to continuously strengthen its R&D
capabilities and accelerate its clinical development programs, in order to fulfil its mission of addressing unmet clinical needs in China
and around the world for the benefit of more patients.
press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section
27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other
than statements of historical facts, contained in this press release may be forward-looking statements, including statements that express
Ascentage Pharma's opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future
results of operations or financial condition. These forward-looking statements are subject to a number of risks and uncertainties as
discussed in Ascentage Pharma's filings with the SEC, including those set forth in the sections titled "Risk factors"
and "Special note regarding forward-looking statements and industry data" in its Registration Statement on Form F-1, as amended,
filed with the SEC on January 21, 2025, the sections headed "Forward-looking Statements" and "Risk Factors" in
the prospectus of the Company for its Hong Kong initial public offering dated October 16, 2019, and other filings with the SEC and/or
The Stock Exchange of Hong Kong Limited we made or make from time to time that may cause actual results, levels of activity, performance
or achievements to be materially different from the information expressed or implied by these forward-looking statements. The forward-looking
statements contained in this presentation do not constitute profit forecast by the Company's management.
a result of these factors, you should not rely on these forward-looking statements as predictions of future events. The forward-looking
statements contained in this press release are based on Ascentage Pharma's current expectations and beliefs concerning future developments
and their potential effects and speak only as of the date of such statements. Ascentage Pharma does not undertake any obligation to update
or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Wan, Head of IR and Strategy